Not a Lexis Advance subscriber? Try it out for free.


Mealey's IP/Tech - Inter Partes Review Of Patented Anti-Diabetic Medication Requested

ALEXANDRIA, Va. - A patent used in three Novo Nordisk A/S diabetes drugs would have been obvious to a person of skill in the art (POSA), a petitioner for inter partes review (IPR) told the Patent Trial and Appeal Board on Dec. 19 (Mylan Institutional LLC v. Novo Nordisk A/S, No. IPR2020-00324, PTAB).
Find full version on lexis Advance®